ChoosingTherapy.com is user-supported. We may earn a commission if you sign up for a service through our links, at no cost to you. Our reviews and comparisons are based on independent research.
- Compounded tirzepatide is a pharmacy-made version of the drug in Zepbound and Mounjaro. It is not FDA-approved, so the FDA doesn’t review its safety, effectiveness, or quality before sale.1
- Compounded tirzepatide is still legal in limited cases. Since March 2025, a pharmacy may compound it for one patient when the prescriber documents a significant clinical difference. The FDA also says that, for now, it doesn’t plan to act on four or fewer prescriptions of a copy a month.2
- The FDA had more than 730 adverse event reports linked to compounded tirzepatide as of May 31, 2026.1 Brand Zepbound vials cost $299 to $449 a month self-pay, by dose, when refilled within 45 days.
Until early 2025, pharmacies could sell copies of tirzepatide at scale because the FDA listed Eli Lilly’s injections as in shortage. Tirzepatide is the drug in Zepbound, approved for weight loss and sleep apnea, and Mounjaro, approved for type 2 diabetes. Compounding means a pharmacy mixes a version of a drug to fill a patient’s prescription. The FDA declared the shortage over in December 2024, and an appeals court upheld that on August 27, 2026. Today, a pharmacy can compound tirzepatide only with a prescription, and only in small volumes or when the prescriber documents why the approved drug doesn’t meet your needs.Sesame Care, a telehealth service, prescribes only FDA-approved GLP-1s such as brand Zepbound, with care from $59 a month plus medication. Talk to a Sesame Care provider about brand Zepbound
ChoosingTherapy.com may earn a commission from the companies whose services are linked on this page.
What is compounded tirzepatide?
Compounded tirzepatide is tirzepatide mixed and labeled by a compounder. The FDA says compounding can be appropriate when an approved drug can’t meet a patient’s needs or isn’t available.1 A 503A pharmacy is state-licensed and works from individual prescriptions. It isn’t held to the FDA’s manufacturing standards (CGMP). A 503B outsourcing facility, a type of compounder created by federal law in 2013, must follow CGMP and is inspected by the FDA.3 Zepbound and Mounjaro are not compounded, and every approved version is an injection under the skin.4 Our tirzepatide guide explains how the drug works.
Ingredients and pill forms
Formulas vary by compounder. A 2026 Annals of Pharmacotherapy study of compounder websites found 33 distinct semaglutide and tirzepatide products in early 2025, about a third of them tirzepatide.5
What compounded tirzepatide is mixed with
The study found 48% of products added vitamin B12, glycine, niacinamide, docusate or the anti-nausea drug ondansetron. The authors saw little justification for the nutrients or docusate.5 Under the 503A rules, a product with an added ingredient is still treated as a copy unless the prescriber documents a significant difference for that patient.2
Is there a compounded tirzepatide pill?
Compounded tirzepatide pills are sold, but no tirzepatide pill or under-the-tongue form is FDA-approved.4 The study’s authors said no advantage of sublingual or dissolving forms over approved oral tablets has been shown.5 Henry Meds sells compounded tirzepatide only as a daily dissolving tablet. The approved GLP-1 pills for weight loss, the Wegovy pill and Foundayo, contain no tirzepatide.
Legal status in 2026
The FDA declared the tirzepatide injection shortage resolved on October 2, 2024, and confirmed it on December 19, 2024. A court refused to block that on March 5, 2025, and the grace periods for shortage-era compounding ended that month.2
What 503A pharmacies may still compound
The FDA treats a product as essentially a copy of Zepbound or Mounjaro when it has the same active ingredient, a similar strength, and the same route. It isn’t treated as a copy when the prescriber documents a significant difference for that individual patient. Otherwise, the FDA says it does not intend, at this time, to act against a pharmacy filling four or fewer copy prescriptions a month.2
503B outsourcing facilities
An outsourcing facility can compound from bulk only if the substance is on the FDA’s 503B bulks list or the drug is in shortage. Tirzepatide is not on the list and is not in shortage.2 On April 30, 2026, the FDA proposed excluding tirzepatide, semaglutide, and liraglutide from that list, finding no clinical need.6 Comments closed July 30, 2026,7 and no final decision had been published as of October 19, 2026.
FDA warning letters and 2026 enforcement
The FDA began a crackdown on telehealth marketing of compounded GLP-1s in September 2025.8 On February 6, 2026, the FDA said it would restrict GLP-1 ingredients used in mass-marketed compounded drugs and warned of possible seizure or injunction.9 On March 3, 2026, it announced letters to 30 more telehealth companies. It said it had sent thousands of letters in six months, more than in the preceding decade.8
The Fifth Circuit ruling
The Outsourcing Facilities Association sued over the shortage decision, with Eli Lilly on the FDA’s side. On August 27, 2026, the Fifth Circuit affirmed judgment for the FDA, holding the decision was not arbitrary or capricious.10
Is compounded tirzepatide banned?
Compounded tirzepatide is banned as regular or large-volume copies and as bulk compounding by outsourcing facilities, both since March 2025.2 A 503A pharmacy can still fill your prescription when the prescriber documents a significant clinical difference, or in the small volumes the FDA has said it won’t act on for now.Compounded tirzepatide is still available to buy with a prescription filled by a licensed pharmacy. Henry Meds sells it as a tablet. Sesame Care prescribes only brand GLP-1s, and Hims lists only brand GLP-1s for weight loss.The FDA’s 503B proposal would formally exclude tirzepatide for outsourcing facilities, and it is not final.6 The FDA urges consumers not to buy products labeled “for research purposes” or “not for human consumption”.1
Safety problems in the FDA’s reports
As of May 31, 2026, the FDA had more than 730 adverse event reports linked to compounded tirzepatide. The total is likely an undercount, because 503A pharmacies don’t have to report.1 Many reported events match the approved drugs’ known side effects.Some reports may involve doses beyond the approved label, such as larger or more frequent doses or faster increases. Some patients sought medical care for nausea, vomiting, diarrhea or abdominal pain.1 The FDA has also seen dosing errors with compounded semaglutide injections. It tells patients to ask their prescriber or compounder how to measure each dose.The FDA knows of fake compounded semaglutide and tirzepatide, some labeled with pharmacies that don’t exist. Counterfeits can hold the wrong ingredient or none.1 Zepbound’s label carries a boxed warning on thyroid C-cell tumors seen in rats.11 Problems can be reported to the FDA’s MedWatch program.
Does compounded tirzepatide work?
Compounded tirzepatide’s effectiveness is unknown because it was not the product studied in Zepbound’s trials. Zepbound’s 72-week trial enrolled 2,539 adults with obesity or overweight and no type 2 diabetes. With diet and exercise, average weight loss ranged from 15.0% to 20.9% across doses, versus 3.1% on placebo.11 Henry Meds’ product page says approved-drug trial data shouldn’t be used to judge compounded versions. We found no randomized trial of compounded tirzepatide, and the 2026 study cites a lack of evidence on safety and efficacy.5 Henry Meds’ Trustpilot page is rated 4.4 across more than 12,500 reviews. Tirzepatide reviewers in 2025 and early 2026 repeatedly complain that the oral tablets did little. Positive reviews praise the staff.This article is for information only and is not medical advice. Talk to a doctor or licensed clinician before starting, stopping, or changing any treatment. If you are in crisis, call or text 988, the Suicide and Crisis Lifeline. For a medical emergency, call 911.
Cost and practical details
Compounded tirzepatide prices vary by seller and form.
| Henry Meds | Compounded tablets | $1,047 per plan, $891 paid in full |
| HealthRx (seen September 28) | Compounded injections | $193 first month, then $214 a month |
| LillyDirect vials | Brand Zepbound | $299 to $449 a month, refilled within 45 days |
| Sesame Care | Visits, labs, brand GLP-1s | $59 to $99 a month, plus medication |
| Hims | Membership, brand GLP-1s | $39 first month, then $149 a month, plus medication |
Prices as of October 19, 2026. Henry’s plan entry lists a 3-month supply but describes 6 months of deliveries.
Dosing and storage
Compounded tirzepatide has no FDA-labeled dose; your prescriber sets the dose, and the pharmacy label shows it. The FDA says not to use injections that arrive warm, and to discard multi-dose vials 28 days after first use.1 Only 18% of compounded products in the 2026 study listed storage conditions.5
Compounded tirzepatide vs Zepbound
Zepbound passed FDA review for safety, effectiveness, and quality. The FDA doesn’t review compounded versions before sale, and formulas vary by pharmacy. See our Zepbound guide and our compounded semaglutide guide for semaglutide, the drug in Wegovy.
Getting brand tirzepatide through Sesame Care
Sesame Care providers prescribe only FDA-approved GLP-1s, including Zepbound vials and KwikPens, when clinically appropriate.Success by Sesame covers video visits, labs, and messaging for $59 a month on an annual plan or $99 per month on a month-to-month plan. Some providers charge more. Self-pay Zepbound goes to LillyDirect. On an annual plan, the 2.5 mg starting-dose vial brings the total to $358/month. Higher doses cost more. Sesame doesn’t bill insurance for visits, but providers handle prior authorization for covered drugs. Cancel at least 3 hours before your first visit for a full refund. Book a Sesame Care visit to ask about brand Zepbound
Where to buy compounded tirzepatide
Every legal source of compounded tirzepatide requires a prescription.
Do you need a prescription for compounded tirzepatide?
You need a prescription for compounded tirzepatide. A 503A pharmacy compounds for an identified individual patient.12 The FDA tells patients to get a prescription and fill it at a state-licensed pharmacy.1 Tirzepatide isn’t a controlled substance, so a telehealth prescriber can write it.
Who sells and prescribes it
At Henry Meds, licensed clinicians from independent medical groups prescribe the tablets. Unnamed licensed US compounding pharmacies mail them in 8 to 10 business days. The evaluation is free, and you pay only if prescribed. Our Henry Meds legitimacy check has more. Sesame Care’s MDs, DOs, nurse practitioners, and physician assistants prescribe only brand GLP-1s, and Hims shows only brand GLP-1s on its weight-loss page.
Signs of an illegal seller
The FDA lists warning signs for online GLP-1 sellers.1 Avoid any company that:
- says its compounded drug is the same as an FDA-approved one
- offers prices that seem too good to be true
- doesn’t require a screening and prescription from a licensed doctor
- ships medicine that looks different, arrives damaged, or lacks instructions
- prints spelling errors, wrong addresses, or a doubtful pharmacy name on the label
- labels tirzepatide “for research purposes”
If you’d rather use the FDA-approved drug, a Sesame Care provider can prescribe Zepbound. See Sesame Care’s FDA-approved weight-loss medication options
Frequently Asked Questions
What does compounded tirzepatide mean?
Compounded tirzepatide means tirzepatide mixed and labeled by a pharmacy, separate from Lilly’s Zepbound and Mounjaro. It is not FDA-approved, and its formula varies by pharmacy.
Is tirzepatide compounded?
Some pharmacies compound tirzepatide, but brand Zepbound and Mounjaro are not. Compounded versions are separate pharmacy products.
What is in compounded tirzepatide?
Compounded tirzepatide contains tirzepatide and often an add-in such as vitamin B12, glycine or niacinamide. A 2026 study found add-ins in 48% of the compounded semaglutide and tirzepatide products it reviewed.
Is compounded tirzepatide FDA approved?
Compounded tirzepatide is not FDA-approved. The FDA says compounding can be appropriate when an approved drug can’t meet a patient’s needs or isn’t available.
Is compounded tirzepatide still available?
Compounded tirzepatide is still available with a prescription from 503A pharmacies, often through telehealth services. Pharmacies can make it only in small volumes or when the prescriber documents a significant clinical difference. Henry Meds sells it as dissolving tablets.
Can you still buy compounded tirzepatide online?
You can still buy compounded tirzepatide online with a prescription from a state-licensed pharmacy. Avoid sellers that skip the prescription.
Will compounded tirzepatide be banned?
Compounded tirzepatide could face a formal 503B exclusion the FDA proposed in April 2026, but it had not published a final decision as of October 19, 2026. The proposal covers outsourcing facilities.
What has the FDA said about compounded tirzepatide?
The FDA has said compounded tirzepatide is not approved and has logged more than 730 adverse event reports as of May 31, 2026. It has also warned telehealth sellers against claiming a compounded drug is the same as an FDA-approved one.
Does compounded tirzepatide work for weight loss?
Compounded tirzepatide is unproven for weight loss because Zepbound’s trials tested only the approved drug. We found no randomized trial of a compounded version.
Is compounded tirzepatide the same as Zepbound?
Compounded tirzepatide is not the same as Zepbound, which passed FDA review. The FDA has warned sellers against making that claim.
Does Sesame Care prescribe compounded tirzepatide?
Sesame Care does not prescribe compounded tirzepatide. Its providers prescribe brand Zepbound, with self-pay vials starting at $299 a month through LillyDirect, plus the program fee.
ChoosingTherapy.com strives to provide our readers with mental health content that is accurate and actionable. We have high standards for what can be cited within our articles. Acceptable sources include government agencies, universities and colleges, scholarly journals, industry and professional associations, and other high-integrity sources of mental health journalism. Learn more by reviewing our full editorial policy.
- U.S. Food and Drug Administration. (2026, October). FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Retrieved from: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- U.S. Food and Drug Administration. (2026, April). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Retrieved from: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- U.S. Food and Drug Administration. (2025, September). Compounding and the FDA: Questions and Answers. Retrieved from: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- U.S. Food and Drug Administration. (2026, October). Drugs@FDA: tirzepatide products. Retrieved from: https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22tirzepatide%22
- Belcourt J, Sapowadia A, White CM. (2026, February). Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. Annals of Pharmacotherapy. Retrieved from: https://doi.org/10.1177/10600280261421979
- U.S. Food and Drug Administration. (2026, April). FDA proposes to exclude semaglutide, tirzepatide and liraglutide from 503B bulks list. Retrieved from: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- Federal Register. (2026, June). List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; extension of comment period. Retrieved from: https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- U.S. Food and Drug Administration. (2026, March). FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. Retrieved from: https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
- U.S. Food and Drug Administration. (2026, February). FDA intends to take action against non-FDA-approved GLP-1 drugs. Retrieved from: https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
- U.S. Court of Appeals for the Fifth Circuit. (2026, August). Outsourcing Facilities Association v. FDA, No. 25-10600. Retrieved from: https://www.ca5.uscourts.gov/opinions/unpub/25/25-10600.0.pdf
- U.S. Food and Drug Administration. (2026, August). ZEPBOUND (tirzepatide) injection prescribing information. Retrieved from: https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ZEPBOUND%22
- Legal Information Institute, Cornell Law School. (2026, October). 21 U.S. Code § 353a: Pharmacy compounding. Retrieved from: https://www.law.cornell.edu/uscode/text/21/353a
We regularly update the articles on ChoosingTherapy.com to ensure we continue to reflect scientific consensus on the topics we cover, to incorporate new research into our articles, and to better answer our audience’s questions. When our content undergoes a significant revision, we summarize the changes that were made and the date on which they occurred. We also record the authors and medical reviewers who contributed to previous versions of the article. Read more about our editorial policies here.
Author: Patricia Duggan, LCMHC
Reviewer: MD review pending